Conformationally constrained 5-(thienyl)tryptamine derivatives as serotonin 5-HT(1B/1D) receptor agonists: Potential treatments for migraine

Medicinal Chemistry Research

Volumn 9, Issue 9, 1999, Pages 668-674

  Slassi, Abdelmalik ^a   Meng, Charles Q ^a,b   Dyne, Kerry ^a,c   Wang, Xin ^a   Lee, David K H ^a,c   Kamboj, Rajender ^a   McCallum, Kirk L ^a   Mazzocco, Lucy ^a   Rakhit, Suman ^a,d  

^a NPS Pharmaceutical Inc   (United States)

^b AtheroGenics Inc   (United States)

^c Department of Pharmacology   (Canada)

^d MCR Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (THIENYL)TRYPTAMINE DERIVATIVE; 3 (THIENYL)TRYPTAMINE DERIVATIVE; 5 (THIENYL)TRYPTAMINE DERIVATIVE; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; MASS SPECTROMETRY; MIGRAINE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RABBIT; SAPHENOUS VEIN; TRIGEMINUS GANGLION; VENOCONSTRICTION;

EID: 0033494873     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 1. Sandler, M.; Ferrari, M.; Harnett, S. ed. Migraine: Pharmacology and Genetics, Altman: London, 1996
2. 2. Stewart W. F.; Lipton, R. B.; Celentano, D.D.; Reed, M.L. JAMA. 1992, 267, 64.
3. 3. Meng, C. Q. Curr. Med. Chem. 1997, 4, 385
4. 4. Visser, W. H.; Burggaraaf, J.; Muller, L. M.; Schoemarker, R. C.; Fowler, P. A.; Cohen, A. F. and Ferrari, M. D. Clin. Pharmacol. & Therapeutic, 1996, 60, 452.
5. 5. Sandler, M.; Ferrari, M. and Harnett, S. Eds. Chapman & Hall, London, 1996, 82.
6. 6. Moskowitz, M. A. Neurology, 1993; 43 (suppl 3), S16-S20.
7. 7. Moskowitz, M. A. and Macfarlane, R. Cerebrovasc Brain Metab Rev. 1993, 5, 159.
8. 8. (a) Moskowitz, M. A. in Migraine Pharmacology and Genetics, Altman: London, 1996;
9. (b) Sandler, M.; Ferrari, M. and Harnett, S. Eds. Chapman & Hall, London, 1996, 144.
10. 9. Phebus, L. A.; Johnson, K. W.; Audia, J. E; Cohen, M. L.; Bresman, B. A.; Fritz, J. E.; Kaldor, S. W.; Krushinski, J. H.; Zgombick, K. W.; Branchek, T. A.; Adam, N. and Schaus, J. M. Neurosci. Abstr., 1996, 22, 1331.
11. 10. Audia, J. H.; Cohen, M. L.; Johnson, K. W. and Phebus, L. A. EP 0 705 600 A1, 10.04.996.
12. 11. Ottervanger, J. P.; Van Witsen, T. B.; Valkenburg, H. A.; Grobbee, D. E.; Stricker, B. H. C, Eur. J. Clin. Pharmacol. 1994, 47, 305.
13. 12. Castro, J. L.; Collins, I.; Russell. M. G. N.; Watt, A. P.; Sohal, B.; Rathbone, D.; Beer, M. S.; Stanton, J. A. J. Med. Chem. 1998, 41, 2667.
14. 13. Ennis, M. E.; Ghazal, R. L.; Smith, M. W.; Schlachter, S. K.; Lawson, C. F.; Im, W. B.; Pregenzer, J. F.; Svensson, K. A.; Lewis, R. A.; Hall, E. D.; Sutter, D. M.; Harris, L. T.; McCall, R. B. J. Med. Chem. 1998, 41, 2180.
15. 14. (a) Meng, C. Q.; Rakhit, S; Lee, D. K. H; Kamboj, R.; McCallum, K.; Mazzocco, L.; Dyne, K. and Slassi, A. (submitted to Bioorg. Med. Chem. Lett.);
16. (b) Slassi, A.; Meng, C. Q; Lee, D. K. H.; Dyne, K. Kamboj, R.; McCallum, K.; Mazzocco, L. and .; Rakhit, S. (submitted to Bioorg. Med. Chem. Lett.)
17. 15. (a) Macor, J. E.; Blake, J.; Fox, C. B.; Johnson, C.; Koe, B. K.; Lebel, L. A.; Morrone, J. M.; Ryan, K.; Schmidt, A. W.; Schulz, D. W. and Zorn, S. H. J. Med. Chem. 1992, 35, 4503;
18. (b) Macor, J. E.; Blank, D. H.; Fox, C. B.; Lebel, L. A.; Newman, M. E.; Ronald J. P.; Ryan, K.; Schmidt, A. W.; Schultz, D. W. and Koe, B. K. J. Med. Chem. 1994, 37, 2509;
19. (c) Macor, J. E.; Chenard, B. L. and Post, R. J. J. Med. Chem. 1994, 59, 7496.
20. 16. Miyaura, N.; Yanagi, T.; Suzuki, A. Synth. Commun. 1981, 11, 513.
21. 17. Macor, J. E.; Blank, D. H.; Post, R. J. Tet. Lett. 1994, 35, 45.
22. 18. Veldman, S. A.; Bienkowski, M. J. Mol. Pharmacol. 1992, 42, 439.
23. 19. Martin G. R.; Mc Lennon S. J. Naunyn-Schmiedeb. Arch. Pharmacology 1990, 342, 111